Last reviewed · How we verify

Novartis Investigational H5N1 vaccine

Seqirus · Phase 3 active Biologic

Novartis Investigational H5N1 vaccine is a Vaccine Biologic drug developed by Seqirus. It is currently in Phase 3 development for Prevention of H5N1 avian influenza infection in at-risk populations.

This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus.

This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus. Used for Prevention of H5N1 avian influenza infection in at-risk populations.

At a glance

Generic nameNovartis Investigational H5N1 vaccine
SponsorSeqirus
Drug classVaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The H5N1 vaccine contains inactivated or recombinant viral antigens that train the adaptive immune system to recognize and respond to H5N1 avian influenza. Upon exposure to the actual virus, the pre-existing immune memory enables rapid production of neutralizing antibodies and T-cell responses to prevent infection or reduce disease severity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Novartis Investigational H5N1 vaccine

What is Novartis Investigational H5N1 vaccine?

Novartis Investigational H5N1 vaccine is a Vaccine drug developed by Seqirus, indicated for Prevention of H5N1 avian influenza infection in at-risk populations.

How does Novartis Investigational H5N1 vaccine work?

This vaccine stimulates the immune system to produce antibodies and cellular immunity against H5N1 influenza virus.

What is Novartis Investigational H5N1 vaccine used for?

Novartis Investigational H5N1 vaccine is indicated for Prevention of H5N1 avian influenza infection in at-risk populations.

Who makes Novartis Investigational H5N1 vaccine?

Novartis Investigational H5N1 vaccine is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What drug class is Novartis Investigational H5N1 vaccine in?

Novartis Investigational H5N1 vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is Novartis Investigational H5N1 vaccine in?

Novartis Investigational H5N1 vaccine is in Phase 3.

What are the side effects of Novartis Investigational H5N1 vaccine?

Common side effects of Novartis Investigational H5N1 vaccine include Injection site pain or erythema, Myalgia, Headache, Fatigue, Fever.

Related